Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Okamoto

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Avian Pathology : Journal of the W.V.P.A|January 1, 1992
Characterization of very virulent Marek's disease viruses isolated in JapanK Imai, N Yuasa, H Iwakiri, et al.
International Journal of Oncology|April 18, 1998
Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomasJ I Sasaki, K K Tanabe, K Takahashi, et al.
British Journal of Cancer|July 17, 1999
Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridizationI Okamoto, H Pirc-Danoewinata, J Ackermann, et al.
Oncogene|March 2, 1999
CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migrationI Okamoto, Y Kawano, H Tsuiki, et al.
British Journal of Cancer|May 3, 2007
The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivoY Akashi, I Okamoto, M Suzuki, et al.
Lung Cancer (Amsterdam, Netherlands)|December 6, 2020
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 studyN Yamamoto, T Seto, M Nishio, et al.
Oncogene|May 12, 2015
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinibK Yonesaka, K Hirotani, H Kawakami, et al.
Bone Marrow Transplantation|March 1, 1994
Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemiaS Takahashi, S I Okamoto, N Shirafuji, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2014
Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancerT Naito, T Seto, K Takeda, et al.
British Journal of Cancer|February 7, 2008
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusY Akashi, I Okamoto, T Iwasa, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Avian Pathology : Journal of the W.V.P.A|January 1, 1992
Characterization of very virulent Marek's disease viruses isolated in JapanK Imai, N Yuasa, H Iwakiri, et al.
International Journal of Oncology|April 18, 1998
Expression of CD44 splicing isoforms in lung cancers: dominant expression of CD44v8-10 in non-small cell lung carcinomasJ I Sasaki, K K Tanabe, K Takahashi, et al.
British Journal of Cancer|July 17, 1999
Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridizationI Okamoto, H Pirc-Danoewinata, J Ackermann, et al.
Oncogene|March 2, 1999
CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migrationI Okamoto, Y Kawano, H Tsuiki, et al.
British Journal of Cancer|May 3, 2007
The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivoY Akashi, I Okamoto, M Suzuki, et al.
Lung Cancer (Amsterdam, Netherlands)|December 6, 2020
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 studyN Yamamoto, T Seto, M Nishio, et al.
Oncogene|May 12, 2015
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinibK Yonesaka, K Hirotani, H Kawakami, et al.
Bone Marrow Transplantation|March 1, 1994
Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemiaS Takahashi, S I Okamoto, N Shirafuji, et al.
Lung Cancer (Amsterdam, Netherlands)|December 3, 2014
Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancerT Naito, T Seto, K Takeda, et al.
British Journal of Cancer|February 7, 2008
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusY Akashi, I Okamoto, T Iwasa, et al.
Pageof 11